In the last trading session, 0.27 million shares of the Gain Therapeutics Inc (NASDAQ:GANX) were traded, and its beta was 0.15. Most recently the company’s share price was $2.28, and it changed around -$0.09 or -3.80% from the last close, which brings the market valuation of the company to $60.48M. GANX currently trades at a discount to its 52-week high of $5.33, offering almost -133.77% off that amount. The share price’s 52-week low was $0.89, which indicates that the current value has risen by an impressive 60.96% since then. We note from Gain Therapeutics Inc’s average daily trading volume that its 10-day average is 0.19 million shares, with the 3-month average coming to 263.98K.
Gain Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 6 analysts rate the stock as a Sell; another 3 rate it as Overweight. Among the rest, 0 recommended GANX as a Hold, whereas 3 deemed it a Buy, and 0 rated it as Underweight.
Gain Therapeutics Inc (NASDAQ:GANX) trade information
Instantly GANX has showed a red trend with a performance of -3.80% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.47 on recent trading dayincreased the stock’s daily price by 7.69%. The company’s shares are currently up 5.56% year-to-date, but still down -0.87% over the last five days. On the other hand, Gain Therapeutics Inc (NASDAQ:GANX) is 37.35% up in the 30-day period. We can see from the shorts that 0.66 million shares have been sold at a short interest cover period of 1.65 day(s).
The consensus price target as assigned by Wall Street analysts is $7, which translates to bulls needing to increase their stock price by 67.43% from its current value. Analyst projections state that GANX is forecast to be at a low of $4 and a high of $10.
Gain Therapeutics Inc (GANX) estimates and forecasts
Gain Therapeutics Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have risen 86.89 percent over the past six months and at a 41.52% annual growth rate that is well above the industry average of 16.60%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -79.01%.
GANX Dividends
Gain Therapeutics Inc’s next quarterly earnings report is expected to be released in February.
Gain Therapeutics Inc (NASDAQ:GANX)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 5.09% of Gain Therapeutics Inc shares, and 7.96% of them are in the hands of institutional investors. The stock currently has a share float of 8.39%. Gain Therapeutics Inc stock is held by 24.0 institutions, with TIMELO INVESTMENT MANAGEMENT INC. being the largest institutional investor. By 2024-06-30, it held 3.3666% of the shares, which is about 0.61 million shares worth $0.77 million.
DME CAPITAL MANAGEMENT, LP, with 3.1488% or 0.57 million shares worth $0.72 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
